Abstract
Although therapy of CD30-positive lymphomas such as classical Hodgkin lymphoma and anaplastic large cell lymphoma has been improved considerably during the last decades, patients suffer from high toxicity of current therapeutic regimens. Since CD30 expression is very restricted, CD30-positive tumors are well suited for immunotherapeutic approaches. Several distinct immunotherapeutic approaches with chimeric, humanized, and bispecific antibodies as well as immunotoxins are already described. In this report, we give a short overview of CD30-targeting approaches in humans. Furthermore, we introduce two novel anti-CD30 fusion proteins consisting of the single chain variable fragment of the CD30 monoclonal antibody Ber-H2 and human interleukin-2, evaluate their biological activity in a human CD30-positive syngeneic murine model, and demonstrate the immunological mechanisms leading to tumor rejection by these reagents. The data indicate that there are several promising approaches in CD30-targeted immunotherapy. The findings of the anti- CD30 IL-2 constructs suggest that these fusion proteins are particularly useful to remove small, residual tumors.
Keywords: Immunotherapy, lymphoma, CD30, IL-2, fusion protein
Current Drug Targets
Title: Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo
Volume: 10 Issue: 2
Author(s): B. Hirsch, J. Brauer, M. Fischdick, C. Loddenkemper, S. Bulfone-Paus, H. Stein and H. Durkop
Affiliation:
Keywords: Immunotherapy, lymphoma, CD30, IL-2, fusion protein
Abstract: Although therapy of CD30-positive lymphomas such as classical Hodgkin lymphoma and anaplastic large cell lymphoma has been improved considerably during the last decades, patients suffer from high toxicity of current therapeutic regimens. Since CD30 expression is very restricted, CD30-positive tumors are well suited for immunotherapeutic approaches. Several distinct immunotherapeutic approaches with chimeric, humanized, and bispecific antibodies as well as immunotoxins are already described. In this report, we give a short overview of CD30-targeting approaches in humans. Furthermore, we introduce two novel anti-CD30 fusion proteins consisting of the single chain variable fragment of the CD30 monoclonal antibody Ber-H2 and human interleukin-2, evaluate their biological activity in a human CD30-positive syngeneic murine model, and demonstrate the immunological mechanisms leading to tumor rejection by these reagents. The data indicate that there are several promising approaches in CD30-targeted immunotherapy. The findings of the anti- CD30 IL-2 constructs suggest that these fusion proteins are particularly useful to remove small, residual tumors.
Export Options
About this article
Cite this article as:
Hirsch B., Brauer J., Fischdick M., Loddenkemper C., Bulfone-Paus S., Stein H. and Durkop H., Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354566
DOI https://dx.doi.org/10.2174/138945009787354566 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis
Reviews on Recent Clinical Trials The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Virulence Factors of Helicobacter pylori: Practical Biomarkers
Recent Patents on Biomarkers Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery (1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in Cancer
Current Topics in Medicinal Chemistry What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Autophagy Driven Extracellular Vesicles in the Leukaemic Microenvironment
Current Cancer Drug Targets Subject Index to Volume 10
Current Pharmaceutical Design Prospecting for New Inhibitors of Anaplastic Lymphoma Kinase, A Clinically Relevant Oncogenic Drug Target
Current Bioactive Compounds Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry